Haleon (HLN)
9.02
-0.08 (-0.88%)
At close: Jan 14, 2025, 3:59 PM
9.17
1.66%
Pre-market Jan 15, 2025, 04:52 AM EST
undefined% (undefined)
| Bid | 9.16 |
| Market Cap | 40.83B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.32 |
| PE Ratio (ttm) | 28.19 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 9.17 |
| Volume | 17,728,665 |
| Avg. Volume (20D) | 6,502,963 |
| Open | 9.09 |
| Previous Close | 9.10 |
| Day's Range | 8.86 - 9.10 |
| 52-Week Range | 7.89 - 10.80 |
| Beta | undefined |
About HLN
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensod...
Sector Healthcare
IPO Date Jul 25, 2022
Employees 25,408
Stock Exchange NYSE
Ticker Symbol HLN
Website https://www.haleon.com
Analyst Forecast
According to 2 analyst ratings, the average rating for HLN stock is "Buy." The 12-month stock price forecast is $10.47, which is an increase of 16.08% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Haleon is scheduled to release its earnings on Feb 27, 2025,
before market opens.
Analysts project revenue of $11.05B, reflecting a -21.37% YoY shrinking and earnings per share of 0.31, making a 40.91% increase YoY.
Analysts project revenue of $11.05B, reflecting a -21.37% YoY shrinking and earnings per share of 0.31, making a 40.91% increase YoY.
10 months ago ·
Source
-2.29%
Haleon shares are trading lower after Pfizer annou...
Unlock content with
Pro Subscription
10 months ago ·
Source
+6.2%
Haleon shares are trading higher. The company reported FY23 revenue results.
